Aurora Launches New European Websites, Showcasing Science-Backed Cannabis Leadership

Rhea-AI Summary

Aurora (NASDAQ: ACB) launched four new, localized European websites on Feb 3, 2026 to support key medical markets and a central hub at auroramedicine.com.

The sites target Germany, the UK and Poland in native languages, spotlight Canadian and local manufacturing, emphasize science-backed quality and provide resources for healthcare professionals, partners and prospective employees to strengthen regional engagement.

News Market Reaction – ACB

+3.57% 1.8x vol

14 alerts

+3.57% Session close to close

-4.7% Trough in 2 hr 56 min

$217.18M Market Cap

1.8x Rel. Volume

In the Feb 3 session, ACB gained 3.57%, reflecting a moderate positive market reaction. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Aurora’s effort to deepen its European medical presence through 4 local...

Analysis

This announcement highlights Aurora’s effort to deepen its European medical presence through 4 localized websites connecting Germany, the UK and Poland via a central hub. It follows recent steps such as new product launches in key EU markets and progress in disease resistance research. Taken together, these moves underscore a focus on science-backed positioning and regional tailoring. Investors may watch upcoming financial results and further EU developments to gauge how this strategy translates into performance.

Key Figures

New websites: 4 websites

1 metrics

New websites 4 websites Launch of central European hub and regional sites for Germany, UK, Poland

Historical Context

5 past events · Latest: Jan 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 21	Earnings call schedule	Positive	+2.1%	Set date and time for Q3 2026 results release and investor call.
Jan 20	IP and genetics update	Positive	-2.1%	Granted EU Community Plant Variety Rights for two proprietary cannabis varieties.
Jan 14	R&D progress	Positive	+0.5%	Reported significant progress on powdery mildew resistance research and trials.
Dec 18	Product launch Germany	Positive	-3.4%	Launched Daily Special medical cannabis brand targeting affordability in Germany.
Dec 11	Product launch Poland	Positive	+0.4%	Introduced Black Jelly high-potency medical flower product in Poland.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent operational and R&D updates have mostly been positive in tone, but price reactions have alternated between gains and losses, indicating inconsistent alignment between upbeat news flow and short-term market response.

Recent Company History

Over the past few months, Aurora has focused on strengthening its European and global medical cannabis position. On Dec 11, 2025, it expanded high‑potency medical flower in Poland, followed by the Dec 18, 2025 launch of Daily Special in Germany. In January 2026, it reported progress in disease resistance research and secured EU plant variety rights, then scheduled its Q3 2026 results call for Feb 4, 2026. The new European websites extend this strategy of regional focus and scientific positioning.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASDAQ | TSX: ACB

Launch of improved, localized websites underscores Aurora's long-term strategy for growth and engagement across key European medical markets

EDMONTON, AB, Feb. 3, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the launch of four brand new websites to support key European markets, continuing its investment in the region through a more focused, locally-relevant digital presence. The refreshed platforms are designed to better reflect Aurora's science-backed approach, manufacturing expertise, and brand strength, while improving engagement with healthcare professionals, partners, and prospective employees across Europe. The central European site, www.auroramedicine.com, provides easy access to the dedicated regional sites for Germany, the UK, and Poland.

"Our new European websites are a demonstration of our ongoing investment and long-term commitment to Aurora's fastest growing region," says Andreas Dotterweich, Senior Vice President, Aurora Europe. "The sites leverage our global leadership in medical cannabis, putting our products, scientific expertise and partnerships front and centre, providing enhanced resources for healthcare practitioners and partners looking for a trusted resource. This streamlined digital presence across Europe positions Aurora to drive growth, reinforce our leadership, and deliver lasting value in Europe."

Building on the recent evolution of Aurora's global brand identity, the new regional websites showcase manufacturing excellence, highlighting both Canadian-made and local production through updated videos and photos while emphasizing quality, compliance, and evidence-based processes. Each platform is available in the native language of its market, and all regional sites are seamlessly accessible from the drop-down menu on the central European hub.

The new websites enhance the experience for healthcare practitioners and partners across Europe. Aligned with Aurora's broader European communications strategy, they establish a locally relevant platform that strengthens engagement, showcases the company's leadership, and positions Aurora to capture emerging opportunities in the evolving medical cannabis market.

About Aurora

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora^®, MedReleaf^®, Pedanios^®, IndiMed^™, San Raf^®, Tasty's^™ and Whistler Cannabis Co^™. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis^™.

Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch of the Company's new European-based websites and associated benefits, including to drive growth, reinforce the Company's leadership, and deliver lasting value in Europe; the Company's long-term strategy for growth and engagement across key European medical markets; and the Company's global leadership in medical cannabis and ability to capture emerging opportunities.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-launches-new-european-websites-showcasing-science-backed-cannabis-leadership-302676808.html

SOURCE Aurora Cannabis Inc.

FAQ

What did Aurora (ACB) announce on Feb 3, 2026 about its European websites?

Aurora launched four localized European websites with a central hub at auroramedicine.com. According to Aurora, the rollout includes dedicated sites for Germany, the UK and Poland in native languages, aimed at improving engagement with healthcare professionals, partners and prospective employees across Europe.

How will Aurora's new European websites affect healthcare professional access to information about ACB products?

The sites provide easier, localized access to product and scientific information for healthcare professionals. According to Aurora, the platforms emphasize evidence-based processes, updated videos and photos, and resources tailored to clinical and regulatory needs in each market to support practitioner engagement.

Where is Aurora directing European traffic for its medical cannabis information under the ACB brand?

Aurora is directing regional users to a central European hub at auroramedicine.com with drop-down links to country sites. According to Aurora, the hub centralizes access while each market site remains localized to reflect language, manufacturing details and regional partnerships.

Does Aurora (ACB) highlight manufacturing origins on the new European sites and why does that matter?

Yes, the sites highlight Canadian-made and local production to underscore quality and compliance. According to Aurora, showcasing manufacturing excellence and evidence-based processes aims to reinforce trust with partners and customers and support the company’s leadership position in Europe.

Are Aurora's new European websites available in local languages for ACB markets?

Yes, each regional site is offered in the native language of its market to improve local relevance. According to Aurora, localized content, multimedia and seamless navigation from the central hub are designed to enhance engagement and regional communications effectiveness.